Top Markets
#1 Derive Derive +33.22%
#2 Cross Cross +20.16%
#3 Geodnet Geodnet +12.50%
#4 Gama Token Gama Token +9.18%
#5 Biconomy Biconomy +9.08%
#6 Steakhouse ETH Morpho Vault Steakhouse ETH Morpho Vault +7.14%
#7 Quantum Resistant Ledger Quantum Resistant Ledger +6.82%
#8 The Bitcoin Bull The Bitcoin Bull +6.60%
#9 Cap Cap +6.32%
#10 Based Based +6.22%
Coin of the day
Derive Derive
設定
言語
日本
通貨
USD
テーマ
Creative Medical Technology Holdings, Inc. Creative Medical Technology Holdings, Inc.

Creative Medical Technology Holdings, Inc.

CELZ
株式のランク #35972
Creative Medical Technology Holdings, Inc., a biotechnology firm based in... Creative Medical Technology Holdings, Inc., a biotechnology firm based in Phoenix, Arizona, specializes in advancing adult stem cell treatments. The company's core focus spans several medical fields, including immunology, urology, orthopedics, and neurology. Among its therapeutic offerings are CaverStem, designed to address erectile dysfunction; FemCelz, which aims to restore genital sensitivity and alleviate dryness; StemSpine, developed to treat chronic lower back pain; ImmCelz, intended for stroke patients; and OvaStem, a solution for female infertility.
株価
$1.25
最終同期: 2026-08-14
時価総額
$3.21M
変化（1日）
0.40%
変化（1年）
-60.10%
国
US
取引 Creative Medical Technology Holdings, Inc. (CELZ)

カテゴリー

Healthcare
Creative Medical Technology Holdings, Inc.（CELZ）の利益
2026 時点の利益 TTM: 0
Creative Medical Technology Holdings, Inc. の最新の財務報告によると、同社の現在の利益は 0 です。2026 年には 0 の利益を上げ、これは 2026 年の利益 0 と 同等 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Creative Medical Technology Holdings, Inc. の利益の推移（2026 〜 2026）
各年末の利益
年 利益 変化
提供された日付のデータは十分ではありません。
同業他社の利益
企業 利益 利益の差 国
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE